Cytokinetics vs Roivant Sciences
Cytokinetics reported revenue of $88 million in fiscal 2025, 10.6 times Roivant Sciences' $8 million in fiscal 2025. Cytokinetics' revenue grew 376.6% in its latest year, and Roivant Sciences' fell 71.6%. Cytokinetics had an operating margin of -695.4%, against -6235.7% at Roivant Sciences. Free cash flow was −$535 million at Cytokinetics and −$759 million at Roivant Sciences. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Cytokinetics | Roivant Sciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Mar 31, 2026 |
| Revenue | $88M | $8M |
| Revenue growth | 376.6% | −71.6% |
| Revenue growth a year, last 5 years | 9.5% | −19.0% |
| Gross margin | — | — |
| Operating margin | −695.4% | −6,235.7% |
| Net margin | −891.6% | −3,629.2% |
| Free cash flow | −$535M | −$759M |
| Free cash flow margin | −607.5% | −9,183.5% |
| Return on capital | — | −62.6% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | — | −4.3% |
| Last close | $60.73 | $36.05 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $51.4 million | sold $582.4 million |
| Piotroski F-score | — | 1 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CytokineticsRoivant Sciences
Operating margin
Percent of revenue
CytokineticsRoivant Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CytokineticsRoivant Sciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cytokinetics and Roivant Sciences pages.